Authors

Iris Postmus
Stella Trompet
Harshal A Deshmukh
Michael R Barnes
Xiaohui Li
Helen R Warren
Daniel I Chasman
Kaixin Zhou
Benoit J Arsenault
Louise A Donnelly
Kerri L Wiggins
Christy L Avery
Paula Griffin
QiPing Feng
Kent D Taylor
Guo Li
Daniel S Evans
Albert V Smith
Catherine E de Keyser
Andrew D Johnson
Anton J M de Craen
David J Stott
Brendan M Buckley
Ian Ford
Rudi G J Westendorp
P Eline Slagboom
Naveed Sattar
Patricia B Munroe
Peter Sever
Neil Poulter
Alice Stanton, Royal College of Surgeons in Ireland
Denis C Shields
Eoin O'Brien
Sue Shaw-Hawkins
Y-D Ida Chen
Deborah A Nickerson
Joshua D Smith
Marie Pierre Dubé
S Matthijs Boekholdt
G Kees Hovingh
John J P Kastelein
Paul M McKeigue
John Betteridge
Andrew Neil
Paul N Durrington
Alex Doney
Fiona Carr
Andrew Morris
Mark I McCarthy
Leif Groop
Emma Ahlqvist
Joshua C Bis
Kenneth Rice
Nicholas L Smith
Thomas Lumley
Eric A Whitsel
Til Stürmer
Eric Boerwinkle
Julius S Ngwa
Christopher J O'Donnell
Ramachandran S Vasan
Wei-Qi Wei
Russell A Wilke
Ching-Ti Liu
Fangui Sun
Xiuqing Guo
Susan R Heckbert
Wendy Post
Nona Sotoodehnia
Alice M Arnold
Jeanette M Stafford
Jingzhong Ding
David M Herrington
Stephen B Kritchevsky
Gudny Eiriksdottir
Leonore J Launer
Tamara B Harris
Audrey Y Chu
Franco Giulianini
Jean G MacFadyen
Bryan J Barratt
Fredrik Nyberg
Bruno H Stricker
André G Uitterlinden
Albert Hofman
Fernando Rivadeneira
Valur Emilsson
Oscar H Franco
Paul M Ridker
Vilmundur Gudnason
Yongmei Liu
Joshua C Denny
Christie M Ballantyne
Jerome I Rotter
L Adrienne Cupples
Bruce M Psaty
Colin N A Palmer
Jean-Claude Tardif
Helen M Colhoun
Graham Hitman
Ronald M Krauss
J Wouter Jukema
Mark J Caulfield

Peer Reviewed

1

Document Type

Article

Publication Date

1-1-2014

Keywords

LDL cholesterol, statins.

Funder/Sponsor

Competing financial interests: B.M.P. serves on the Data and Safety Monitoring Board of a clinical trial funded by the device manufacturer (Zoll LifeCor). N.P. and A.S. received funding from Pfizer for the extended follow-up of the ASCOT UK participants. D.I.C. and P.M.R. received research support for independent genetic analysis in JUPITER from AstraZeneca. F.N. and B.J.B. have employment, stock and stock options in AstraZeneca, a for-profit company engaged in the discovery, development, manufacture and marketing of proprietary therapeutics such as rosuvastatin, but do not consider that this creates any conflict of interest with the subject–matter of this publication. R.M.K. serves on the Merck Global Atherosclerosis Advisory Board. The remaining authors declare no competing financial interests.

Abstract

Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation. Here we perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) in studies addressing the LDL cholesterol response to statins, including up to 18,596 statin-treated subjects. We validate the most promising signals in a further 22,318 statin recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we confirm the previously described associations with APOE and LPA. Our findings advance the understanding of the pharmacogenetic architecture of statin response.

Disciplines

Life Sciences

Citation

Postmus, I. et al. Pharmacogenetic meta-analysis of genomewide association studies of LDL cholesterol response to statins. Nature Communications. 2014;5:5068

PubMed ID

25350695

DOI Link

10.1038/ncomms6068

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Included in

Life Sciences Commons

Share

COinS